Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin, NCC to Collaborate on Cancer Meds, Biomarkers
February 1, 2017
- Takeda Obtains Japan Rights to Exelixis’ Cancer Drug
February 1, 2017
- Astellas Gets Rights to US Biotech’s Ruptured Eardrum Med
February 1, 2017
- Major Products Face Impending Listing of Generics, though Patents Remain for Some
February 1, 2017
- Biogen to Keep Its Focus on High Unmet Needs, Win-Win Partnerships: CEO
January 31, 2017
- Latuda OK’ed in US for Adolescent Schizophrenia
January 31, 2017
- Mochida Filed Enbrel Biosimilar in Japan in October-December
January 31, 2017
- Linzess Delivers Positive Japan PIII Data in Chronic Constipation: Astellas
January 31, 2017
- Nippon Chemiphar, Nagase Medicals Win Elplat Patent Suit
January 30, 2017
- Mitsubishi Tanabe, Biogen Terminate MS Licensing Deal
January 30, 2017
- SBI to Initiate UK PII Study of 5-ALA for Prevention of Postoperative Cardiac Output Reduction
January 30, 2017
- Shionogi to Seek Expansion of Pediatric Indication for Sublingual Allergen Immunotherapy Tablet Actair
January 30, 2017
- Chugai to Shuffle Sales Organization to Cater to Community-Based Care
January 27, 2017
- Mochida Will Groom Lialda into Flagship Quickly: President
January 27, 2017
- Daiichi Sankyo Espha to Launch Micardis AG, Will Actively Handle Competitors’ Products
January 27, 2017
- Sumitomo Dainippon Completes Tolero Acquisition
January 27, 2017
- Lenvima Shows Non-Inferiority vs Nexavar in OS as Liver Cancer 1st Line Treatment
January 27, 2017
- Pfizer Adjusts Shipments for Tazopipe, Voluntarily Recalls Metformin Generics
January 27, 2017
- Biogen Japan to Make New Start as MS Powerhouse after Hemophilia Spin-off
January 25, 2017
- Kansai Medico Used Non-Official Harvoni Dealer for Cheaper Price
January 25, 2017
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…